NXTC
NextCure, Inc. Common StockstockNASDAQ
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 5.98 | 2026-11-11 | +14.05% | -0.361 |
| 1M | 5.67 | 2026-10-19 | +20.28% | 3.101 |
| 3M | 6.65 | 2026-08-18 | +2.56% | 2.328 |
| 6M | 9.25 | 2026-05-18 | -26.27% | 2.941 |
| 1Y | 10.00 | 2025-11-18 | -31.80% | 2.413 |
| 2Y | 15.48 | 2024-11-18 | -55.94% | — |
| 5Y | 70.56 | 2021-11-18 | -90.33% | 0.855 |
NextCure, Inc. Common Stock (NASDAQ:NXTC) stock price today is $6.82, and today's volume is 21,405. NXTC is up 1.791% today. The 30 day average volume is 63,909. NXTC market cap is $31.23M with 4.58M shares outstanding.